NASDAQ: SONN - Sonnet BioTherapeutics Holdings, Inc.

Rentabilité sur six mois: -80.42%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions Sonnet BioTherapeutics Holdings, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer and is under phase 1 trial.

plus de détails
The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy and is under Phase Ib/IIa study; and SON-1210, a bispecific compound developed for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2006-10-31
ISIN US83548R2040
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.sonnetbio.com
Цена ао 1.33
Changement de prix par jour: 0% (1.31)
Changement de prix par semaine: -5.07% (1.38)
Changement de prix par mois: -13.82% (1.52)
Changement de prix sur 3 mois: -13.25% (1.51)
Changement de prix sur six mois: -80.42% (6.69)
Changement de prix par an: -29.57% (1.86)
Evolution du prix sur 3 ans: +220.29% (0.409)
Evolution du prix sur 5 ans: +236.07% (0.3898)
Evolution des prix depuis le début de l'année: -16.03% (1.56)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 235.35 1
P/BV -9.02 0
P/E 0 0
EV/EBITDA -0.3684 0
Total: 2.75

Efficacité

Nom Signification Grade
ROA, % -181.38 0
ROE, % 2089.93 10
Total: 3.33

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.011 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -99.94 0
Rentabilité Ebitda, % 12.85 2
Rentabilité EPS, % -75.41 0
Total: 0.4
Plus de détails

Établissements Volume Partager, %
Renaissance Technologies, LLC 43749 1.43
Citadel Advisors Llc 29447 0.96
Vanguard Group Inc 14726 0.48
Tower Research Capital LLC (TRC) 2094 0.07
Blackrock Inc. 594 0.02
Morgan Stanley 61 0
Osaic Holdings Inc 45 0
Wells Fargo & Company 21 0
JP Morgan Chase & Company 19 0
Private Wealth Management Group, LLC 3 0



Superviseur Titre d'emploi Paiement Année de naissance
Dr. Pankaj Mohan Ph.D. Founder, Chairman, CEO & President 927k 1965 (60 années)
Dr. John K. Cini Ph.D. Chief Scientific Officer & Co-Founder 602.48k 1953 (72 année)
Mr. Jay Cross Chief Financial Officer 603.42k 1971 (54 année)
Mr. Donald J. Griffith CPA, CPA Controller & Director 134.05k 1949 (76 années)
Ms. Susan Dexter Chief Technical Officer N/A 1955 (70 années)
Dr. Richard T. Kenney FACP, M.D. Chief Medical Officer N/A 1958 (67 années)
Mr. Manuel Dafonseca Head of Clinical Operations N/A

Adresse: United States, Princeton. NJ, 100 Overlook Center - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.sonnetbio.com